Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive ...

The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.

This data is encouraging as it reinforces the large and growing body of evidence indicating that certepetide can enhance the targeting, penetration, and effectiveness of therapeutic agents - in this ...

A Cornell-led collaboration has devised a potentially low-cost method for producing antibodies for therapeutic treatments. They've bioengineered bacteria with an overlooked enzyme that can attach ...

The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help ...

The deals will bolster Takeda’s ADC portfolio, which the company now considers a key modality focus within its oncology ...

Under the collaboration, Invenra will leverage its proprietary B-Body (R) Bispecific platform and T-Body (TM) Trispecific antibody platform to generate novel multispecific antibody formats, while ...

Researchers are increasingly developing antibody therapies to treat infectious diseases. Therapies are being designed to ...

Protinah, a new drug development company specializing in protein-protein interaction (PPI) big data, announced on November 5 that it has been selected ...

ADCs integrate monoclonal antibodies with cytotoxic payloads, offering new treatment options for NSCLC, including biomarker-selected and biomarker-agnostic patients. ADCs are composed of an antibody, ...

Antibody-based drugs often become too thick to be injected at high concentrations. Now, new research can explain why this happens—knowledge that could eventually lead to easily injectable medications.